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OBJECTIVES This investigation examined the risk of sudden cardiac death and other mortality in adult
patients with hypertrophic cardiomyopathy (HCM) who have myocardial bridging diagnosed
at coronary angiography.
BACKGROUND Several reports have associated myocardial bridging with an adverse prognosis in pediatric
HCM patients, but the prognosis of myocardial bridging in adult patients with HCM is
unknown.
METHODS The coronary angiograms of 425 patients with HCM (mean age 60  15 years [range 18 to
89 years]) at the Mayo Clinic were examined for the presence of myocardial bridging. Clinical
follow-up was conducted to assess mortality. Survival of patients with bridging was compared
with HCM patients who also underwent angiography but who did not have evidence of
bridging.
RESULTS A total of 64 patients (15%) had myocardial bridging. The mean follow-up for the entire
study was 6.8  5.4 years. There was no difference in survival free of all-cause mortality
(5-year estimate, bridging vs. no bridging, 91% vs. 85%; p  0.42), all cardiac death (93% vs.
89%; p  0.60), and sudden cardiac death (95% vs. 97%; p  0.72). Univariate and
multivariate proportional hazards models also did not identify the presence of bridging or
specific characteristics of the degree or extent of bridging with a poor outcome.
CONCLUSIONS This study observed no increased risk of death, including sudden cardiac death, among adult
patients with HCM who had myocardial bridging diagnosed at coronary angiography.
(J Am Coll Cardiol 2003;42:889–94) © 2003 by the American College of Cardiology
Foundation
Myocardial bridging occurs when the epicardial coronary
arteries are intramyocardial, resulting in systolic compres-
sion of a coronary artery on coronary angiography. Myocar-
dial bridging is a well-recognized phenomenon that has a
prevalence of 1% to 3% in the general population (1–3).
Among patients with hypertrophic cardiomyopathy
(HCM), however, this phenomenon is significantly more
frequent, with prevalence rates up to 30% (4,5). In studies of
pediatric patients with HCM, the presence of myocardial
bridging has been associated with the severity of disease,
including nuclear perfusion abnormalities, chest pain, ven-
tricular tachycardia, and increased risk of sudden cardiac
death (SCD) (6,7). However, there has been no study of the
prognostic impact of myocardial bridging in adult patients
with HCM. This investigation was therefore undertaken to
examine the risk of SCD and other mortality in adult
patients with HCM who have myocardial bridging identi-
fied at the time of coronary angiography.
METHODS
Patients. Between November 1978 and March 2001, 2,356
patients with HCM were examined at the Mayo Clinic in
Rochester, Minnesota. Of these patients, 435 who were
18 years of age underwent coronary angiography as part of
their cardiac evaluation. Patients whose stored angiographic
data were not available (n  3) or inadequate for review (n
 7) were excluded, leaving a final study population of 425
patients. In all patients, the diagnosis of HCM was based on
typical clinical, electrocardiographic, and echocardiographic
features, with ventricular myocardial hypertrophy occurring
in the absence of any other cardiac or systemic disease,
which could have caused the observed hypertrophy (8–10).
Each coronary angiogram was retrospectively examined
by an independent observer who had no knowledge of the
patients’ medical history or status (i.e., alive or deceased).
Myocardial bridging was defined as a change in luminal
compression of an epicardial coronary artery of 50%
during systole (Fig. 1). The cineangiographic projection
that demonstrated the greatest degree of bridging was used
to determine maximal systolic compression and the total
length of the bridged segment. Each artery was examined
for the presence of myocardial bridging, maximal percentage
of systolic compression, total length of bridging, and refer-
ence diameter of the bridged segment. Arterial segment
diameters and lengths were determined through calibration
with the known diameter of the coronary artery catheter.
For patients with multiple sites of bridging, the lengths of
each bridged segment were summed to obtain total length.
Standard nomenclature of coronary artery anatomy was
utilized to define the area affected by bridging (11). The
presence of coronary artery disease was defined as luminal
From the Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic
and Mayo Foundation, Rochester, Minnesota. A Scholarly Clinician Award from the
Mayo Foundation supported this study. Barry Maron, MD, acted as the Guest Editor
for this article.
Manuscript received January 21, 2003; revised manuscript received May 2, 2003,
accepted May 13, 2003.
Journal of the American College of Cardiology Vol. 42, No. 5, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00854-4
stenosis of 50% in the left main coronary artery or 70%
in other major epicardial branches (11).
Follow-up evaluation. The Mayo Foundation’s Institu-
tional Review Board approved this study. Clinical follow-up
was conducted through mailed questionnaires and/or tele-
phone contact. For deceased patients, circumstances and the
primary reason for death were sought through procurement
of death certificates and, if possible, medical records and
autopsy reports with permission of the next of kin. In all
cases, death coding was performed by an investigator
blinded to the presence or absence of bridging. Sudden
cardiac death was defined as instantaneous and unexpected
death with or without documented ventricular fibrillation
within 1 h after a witnessed collapse in patients who
previously were in a stable clinical condition or nocturnal
death with no antecedent history of worsening symptoms.
Sudden causes of death that were clearly not organic (e.g.,
homicide) were not counted as being SCD. Appropriate
discharge of an implantable cardioverter-defibrillator (ICD)
device for therapy of lethal arrhythmia (i.e., ventricular
tachycardia or fibrillation) was considered as SCD for end
point analyses. Death due to congestive heart failure was
defined as death occurring in the context of long-standing
cardiac decompensation, with progression of the disease
over the preceding year and development of pulmonary
edema or cardiogenic shock.
Statistical analysis. Primary end points were SCD, death
due to cardiac causes (including SCD), and all-cause mor-
tality. Follow-up for 10 years was censored because the
number of patients with bridging who were at risk fell below
15 after this period. For the end point of all-cause mortality,
the follow-up time was the interval from the date of the
initial evaluation to the time of death or, among survivors,
the date of the follow-up evaluation. The date of angiog-
raphy was considered to be the time of the initial evaluation.
The end point of cardiac death included HCM-related
death (e.g., SCD), the occurrence of either heart transplan-
tation or death due to stroke. The follow-up time was
censored for survivors and patients who dies of either
noncardiac or undetermined causes. For the end point of
SCD, the follow-up time was censored for survivors and
patients who died of other causes.
For survival analyses, patients who either had their
myocardial bridge resected during surgery (n  1) or who
had concomitant coronary artery disease (n  97) were
excluded (of note, the one patient who had bridge resection
also had coronary artery disease). Among this study popu-
lation (n  328), Cox proportional hazards models were
used to identify variables associated with the end points.
Stepwise techniques were used to identify variables inde-
pendently associated with the end point at a significance
level of p  0.10, which were then incorporated into a final
model. The variables considered in the univariate analyses
were age, male gender, presence of myocardial bridging,
maximal percentage of systolic compression, total length of
bridging, reference diameter of the bridged segment, and
Figure 1. Myocardial bridging in a patient with hypertrophic cardiomy-
opathy. Right anterior oblique views of the left coronary artery during
diastole (A) and systole (B). Bridging of the middle left anterior descending
coronary artery (LAD) (black arrows on B) is evident during systole. This was
associated with complete systolic obliteration of the second septal perforator
artery, which is visible only during diastole. There also was mild systolic
compression of the distal LAD.
Abbreviations and Acronyms
CI  confidence interval
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter-defibrillator
LAD  left anterior descending coronary artery
SCD  sudden cardiac death
SM  septal myectomy
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involvement of the left anterior descending coronary artery
(LAD) with bridging. Other clinical variables considered
were severe angina (Canadian Cardiac Society Class III/
IV), severe dyspnea (New York Heart Association func-
tional class III/IV), paroxysmal or chronic atrial fibrillation,
previous stroke or transient ischemic attack, a family history
of sudden death due to HCM, unexplained syncope, max-
imal wall thickness (15 mm, 15 to 19 mm, 20 to 24 mm,
25 to 29 mm, 30 mm), left ventricular outflow tract
obstruction (resting gradient 30 mm Hg or provoked
gradient 50 mm Hg), and septal myectomy (SM).
Because patients with myocardial bridging were consid-
erably younger than patients without myocardial bridging, a
second survival comparison was performed. In this compar-
ison, patients who had bridging but who did not have bridge
resection or coronary artery disease (n  54) were age- and
gender-matched randomly in a 1:1 fashion to patients with
HCM who underwent coronary angiography but who did
not have myocardial bridging (i.e., 54 control subjects).
Patients with coronary artery disease were not eligible for
use as control subjects in this analysis.
The Kaplan-Meier method was used to calculate survival
estimates free of the end point events. Survival estimates are
reported with a 95% confidence interval (CI). A log-rank
test was used to compare survival curves among different
patient groups. In an analysis that matched patients with
bridging to patients without bridging according to age and
gender, Cox models stratified for age and gender were used
to examine survival of the two groups. Contingency tables
were analyzed for the association with a chi-square value, or,
if the patient number in any group was less than five, the
Fisher exact test was used. Comparisons of continuous
variables were made with the Wilcoxon rank-sum test. All
variables are reported as the mean  SD. Statistical signif-
icance was set a priori at p  0.05.
RESULTS
Baseline characteristics. Table 1 lists the baseline charac-
teristics of the study population. Myocardial bridging was
present in 64 patients (15%). Patients with myocardial
bridging were younger and more likely to have a history of
SM than patients without bridging. There was no difference
in symptom status or adverse medical history between
patients with and without bridging. Fifteen (23%) of the
patients with myocardial bridging and 53 (15%) of those
without bridging underwent SM.
The total number of bridged segments identified in the
study population was 67 (Table 2). Most commonly, a
single area of bridging was present. The arterial segment
most frequently involved with bridging was the middle
LAD (85% of cases).
Follow-up data. Clinical follow-up was achieved in 424
(99.7%) of 425 patients. The mean follow-up duration for
the entire study population was 6.8  5.4 years (range 1
month to 24.8 years; median 5.5 years). Ninety-seven
patients with either coronary artery disease at the time of
angiography and/or bridge resection during follow-up were
excluded from survival analyses. Among the remaining 328
patients, there were 58 deaths during the study period.
Fifty-one deaths occurred among the 274 patients with-
out bridging: 34 deaths were cardiac in origin, including 10
Table 1. Baseline Patient Characteristics
Bridging Present
(n  64)
No Bridging
(n  361)
Age (yrs) 53  14 61  14*
Male gender 38 (59) 169 (47)
Dyspnea (NYHA)
Class III/IV 30 (47) 182 (50)
Angina†
Class III/IV 23 (36) 125 (35)
Syncope 9 (14) 47 (13)
Family history of HCM 14 (22) 4 (13)‡
Family history of SCD due to HCM 8 (13) 21 (6)‡
Echocardiographic findings
Mean MLVWT (mm) 19.5  4.9 20.6  5.1
LVOT obstruction 30 (47) 180 (50)
Asymmetric hypertrophy 32 (50) 154 (43)
Concentric hypertrophy 17 (27) 129 (36)
Other hypertrophy 6 (9) 33 (9)
Previous medical history
Atrial fibrillation 8 (13) 72 (20)
Cardiac arrest 1 (2) 5 (1)
CVA and/or TIA 2 (3) 25 (7)
Septal myectomy 6 (9) 11 (3)§
ICD 0 2 (1)
Permanent pacemaker 7 (11) 22 (6)
Current medical therapy 60 (94) 328 (91)
*p  0.0001 (Wilcoxon). †According to the Canadian Cardiovascular Society. ‡p 
0.10 (chi-square). §p 0.05 (chi-square). Data are presented as the mean value SD
or number (%) of subjects.
CVA  cerebral vascular accident; HCM  hypertrophic cardiomyopathy; ICD
 implantable cardioverter-defibrillator; LVOT  left ventricular outflow tract;
MLVWT  maximal left ventricular wall thickness; NYHA  New York Heart
Association; SCD  sudden cardiac death; TIA  transient ischemic attack;
Table 2. Bridging Segment Characteristics
No. vessels with bridging per patient
One 61 (95)
Two 1 (2)
Three 2 (3)
Location
Middle LAD 44 (68)
Middle and distal LAD 11 (17)
Distal LAD 3 (5)
Intermediate branch 3 (5)
Obtuse marginal branch 2 (3)
Proximal LCx 1 (2)
Posterior descending artery 1 (2)
Diagonal branch 1 (2)
Distal RCA 1 (2)
Total length of bridging per patient (mm) 14.5  12.8
Range of total length of bridging per patient (mm) 1.5 to 83.0
Reference vessel diameter (mm) 2.73  1.19
Percent diameter reduction 68  20
Concomitant coronary artery disease 9 (15)
Data are presented as the number (%) of subjects or mean value  SD.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary
artery; RCA  right coronary artery.
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SCDs, 14 deaths due to congestive heart failure, 5 due to
stroke, 3 due to myocardial infarction, 1 due to heart
transplantation, and 1 due to complications related to an
out-of-hospital cardiac arrest. Thirteen patients had non-
cardiac causes of death. Four patients had undetermined
causes. No patient had discharge of an ICD.
Seven deaths occurred among the 54 patients with
myocardial bridging without bridge resection or coronary
artery disease. Two of these deaths were sudden; two were
due to congestive heart failure. Two patients had noncardiac
deaths. The cause of death was unknown in one patient.
Survival analysis. ENTIRE STUDY POPULATION. Patients
with myocardial bridging did not demonstrate a reduction
in survival free of any end point, as compared with HCM
patients who did not have bridging (Fig. 2). Five-year
overall survival was 90.5% (95% CI 83.4% to 99.6%) for
patients with bridging and 84.6% (95% CI 79.9% to 89.3%)
for HCM patients without bridging (p 0.42). For the end
point of cardiac death, this survival was 93.3% (95% CI
85.9% to 100%) among patients with bridging and 88.9%
(95% CI 84.7% to 93.1%) among HCM patients without
bridging (p  0.60). For the end point of SCD, five-year
survival was 95.2% (95% CI 94.1% to 100%) for patients
with bridging and 96.7% (95% CI 94.2% to 99.1%) among
HCM patients without bridging (p  0.72). Specific
characteristics of the degree and extent of bridging were
analyzed. Neither the presence of myocardial bridging, total
length of the bridged segment, maximal percent diameter
reduction, presence of LAD bridging, nor the reference
diameter was associated with the study end points in either
univariate or multivariate analyses that accounted for differ-
ence in age, gender, and other co-variates with statistical
association (Table 3).
AGE- AND GENDER-MATCHED COMPARISON. In compari-
son with age- and gender-matched HCM patients without
myocardial bridging, HCM patients with bridging did not
demonstrate a reduction in survival free of any end point
(Fig. 3). Five-year overall survival was 91.5% (95% CI
83.4% to 99.6%) for patients with bridging and 94.3% (95%
CI 88% to 100%) for control subjects with HCM who did
not have bridging (p  0.71). For the end point of cardiac
death, this survival was 93.3% (95% CI 85.9% to 100%) for
patients with bridging and 94.3% (95% CI 88% to 100%)
for control subjects with HCM who did not have bridging
(p 0.71). For the end point of SCD, five-year survival was
95.2% (95% CI 94.1% to 100.0%) for patients with bridging
and 98.0% (95% CI 88.6% to 100%) for control subjects
with HCM who did not have bridging (p  0.57).
DISCUSSION
Myocardial bridging has been associated with the severity of
cardiac disease and an increased risk of SCD in pediatric
patients with HCM. Because of these reports, there has
been confusion about the need for coronary angiography
and the appropriate intervention once bridging has been
diagnosed in adult HCM patients. The high prevalence of
myocardial bridging in HCM patients underscores the need
for clarification of the clinical significance of myocardial
bridging in adults.
Figure 2. Unadjusted survival comparisons of hypertrophic cardiomyopa-
thy patients with and without myocardial bridging for the study end points
(A overall death; B all cardiac deaths; C sudden cardiac death). The
dashed lines indicate patients with myocardial bridging. The solid lines
indicate patients without myocardial bridging. Comparisons were per-
formed with log-rank analyses.
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In this investigation, myocardial bridging was not asso-
ciated with detrimental long-term outcomes, including an
increased risk of SCD. To date, the current investigation is
the largest reported population of adult patients with HCM
who have myocardial bridging. Survival free of the study end
points (i.e., overall death, cardiac death, SCD) was identical
between patients with and without myocardial bridging.
Although patients with bridging were younger than those
without bridging, bridging was not predictive after adjust-
ment for age (and male gender), nor was it predictive in a
separate analysis with case control for age and male gender.
Proportional hazards analysis also did not identify any
specific bridging segment characteristics to be predictive of
a poor outcome.
There have been a number of reports of unselected
patients and patients with HCM that have associated
myocardial bridging with cardiac morbidity and risk of
death, including SCD. These associations have been ex-
plained by reductions in coronary flow from systolic com-
pression, which could be exacerbated during exercise (12).
However, there are several confounding issues with regard
to the interpretation of these previous studies. Several have
been single case reports of HCM patients that, while
documenting the co-existence of bridging in a patient,
cannot support a causal relation between the presence of
bridging and death (13). Further confounding the interpre-
tation of such data is the fact that bridging is more common
in patients with myocardial hypertrophy, especially HCM.
Patients with HCM have an increased risk of sudden death
and cardiac morbidity as compared with the general popu-
lation. In a study of 23 pediatric patients with HCM, those
with myocardial bridging were more likely to have thallium
perfusion defects, but multivariate analysis demonstrated
that bridging was not predictive of perfusion defects after
adjustment for the degree of septal hypertrophy (7). In young
Table 3. Univariate Analyses for the Association of Bridging
Segment Characteristics With the End Points of Overall Death,
Cardiac Death, and Sudden Cardiac Death
RR 95% CI p Value
Overall death
Bridging present 1.12 0.51 to 2.47 0.77
Total length of bridging 1.01 0.94 to 1.08 0.77
LAD bridging 1.27 0.55 to 2.91 0.57
Reference diameter 1.08 0.55 to 2.11 0.83
Maximal systolic narrowing 0.56 0.02 to 17.6 0.74
Cardiac death
Bridging present 1.05 0.42 to 2.63 0.91
Total length of bridging 0.99 0.92 to 1.08 0.88
LAD bridging 1.27 0.47 to 3.39 0.63
Reference diameter 1.16 0.58 to 2.32 0.16
Maximal systolic narrowing 0.07 0 to 11.27 0.29
Sudden cardiac death
Bridging present 0.67 0.17 to 2.60 0.55
Total length of bridging 0.76 0.48 to 1.18 0.21
LAD bridging 1.10 0.23 to 5.31 0.91
Reference diameter 1.42 0.53 to 3.83 0.48
Maximal systolic narrowing 0 0 to 6  103 0.28
All models were adjusted for age and male gender.
CI  confidence interval; LAD  left anterior descending coronary artery; RR 
risk ratio.
Figure 3. Survival comparisons between hypertrophic cardiomyopathy
(HCM) patients with myocardial bridging (dashed lines) and age- and
gender-matched HCM patients without bridging (solid lines) for the
study end points (A  overall death; B  all cardiac deaths; C  sudden
cardiac death). Comparisons were performed with Cox models stratified
for age and gender.
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patients, the degree of septal hypertrophy itself has been
associated with an increased risk of sudden death (14). In
another case series that excluded patients with hypertrophy,
myocardial bridging was not associated with ischemia (15).
Several studies have specifically examined the hemody-
namic consequences of myocardial bridging and have re-
ported alleviation of cardiac ischemia and symptoms
through surgical relief of myocardial bridging (12,16,17).
This study did not examine any relationship between
bridging and myocardial ischemia. Because the current
investigation focused on survival, it does not dispute the
possibility that therapy directed at the relief of bridging may
be palliative in patients with HCM. However, for the
purposes of identifying patients at an increased risk of death,
coronary angiography for the detection of bridging and its
treatment does not appear to be justified.
Study limitations. This was a select group of patients with
a high incidence of severe symptoms, which reflects the
clinical practice of performing invasive studies in symptom-
atic patients and the nature of our referral population. Thus,
the true incidence of bridging in less symptomatic patients
is unknown. Notably, of 29 patients who resided in Olmsted
County (i.e., nonreferral population), five (17%) had myo-
cardial bridging. This incidence of myocardial bridging was
similar to that of the entire study population (15%). The age
discrepancy between patients with and without bridging
may raise the possibility of premature death (i.e., selection
bias). Further study with prospective screening of patients at
a young age would be required to answer this question.
Patients with myocardial bridging were more likely to have
undergone myectomy than those patients without bridging,
and the effect of surgery on improved survival cannot be
ruled out, although SM following the initial evaluation was
not a predictor of outcomes in this analysis. Another
limitation is that there was not a prospective analysis of the
occurrence of silent ischemia in these patients.
Conclusions. Myocardial bridging is frequent in patients
with HCM. This study observed no increased risk of death,
including SCD, among patients with HCM who had
myocardial bridging, as compared with HCM patients
without bridging.
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